Reply: Potential role of Janus kinase inhibitors in COVID-19 - 19/06/20
Doi : 10.1016/j.jaad.2020.04.098
Maddalena Napolitano, MD a, ⁎ 
, Gabriella Fabbrocini, MD b, Cataldo Patruno, MD, PhD c
, Gabriella Fabbrocini, MD b, Cataldo Patruno, MD, PhD c a Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
b Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
c Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
∗Correspondence to: Dr Maddalena Napolitano, Via Pansini 5, Naples 80131, ItalyVia Pansini 5Naples80131Italy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr Napolitano has acted as a speaker for Sanofi. Dr Fabbrocini has acted as a speaker and consultant for AbbVie and LEO Pharma. Dr Patruno has acted as a speaker and consultant for AbbVie, Novartis, Pfizer, and Sanofi. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 1
P. e65 - juillet 2020 Retour au numéro
Article précédent
- Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak
- Diego Fernandez-Nieto, Juan Jimenez-Cauhe, Ana Suarez-Valle, Oscar M. Moreno-Arrones, David Saceda-Corralo, Arantxa Arana-Raja, Daniel Ortega-Quijano
- Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19
- Danielle Peterson, William Damsky, Brett King
Bienvenue sur EM-consulte, la référence des professionnels de santé.